Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - Sarepta Therapeutics, Inc. | Financial_Report.xls |
| EX-10.2 - SEPARATION AND RELEASE AGREEMENT - Sarepta Therapeutics, Inc. | d230901dex102.htm |
| EX-31.2 - SECTION 302 CFO CERTIFICATION - Sarepta Therapeutics, Inc. | d230901dex312.htm |
| EX-10.1 - SEPARATION AND RELEASE AGREEMENT - Sarepta Therapeutics, Inc. | d230901dex101.htm |
| EX-32.1 - SECTION 906 CEO CERTIFICATION - Sarepta Therapeutics, Inc. | d230901dex321.htm |
| EX-31.1 - SECTION 302 CEO CERTIFICATION - Sarepta Therapeutics, Inc. | d230901dex311.htm |
| EX-32.2 - SECTION 906 CFO CERTIFICATION - Sarepta Therapeutics, Inc. | d230901dex322.htm |
| EX-10.4 - FIRST AMENDMENT TO LEASE DATED AUGUST 30, 2011 - Sarepta Therapeutics, Inc. | d230901dex104.htm |
| 10-Q - FORM 10-Q - Sarepta Therapeutics, Inc. | d230901d10q.htm |
Exhibit 10.3
| AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT | 1. CONTRACT ID CODE V |
PAGE OF PAGES | ||||||||||||||||||||||||||
| 1 | 3 | |||||||||||||||||||||||||||
| 2. AMENDMENT/MODIFICATION NO.
P00005 |
3. EFFECTIVE DATE
08/15/2011 |
4. REQUISITION/PURCHASE REQ. NO.
see schedule |
5. PROJECT NO. (If applicable) | |||||||||||||||||||||||||
| 6. ISSUED BY CODE |
W911QY | 7. ADMINISTERED BY (If other than Item 6) CODE | S4801A | |||||||||||||||||||||||||
|
NATICK CONTRACTING DIVISION 64 Thomas Johnson Drive Frederick MD 21702-4300 |
DCMA DCMA-SEATTLE CORPORATE CAMPUS EAST III 3009 112TH AVE. NE STE200 BELLEVUE WA 98004-8019 | |||||||||||||||||||||||||||
| 8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code)
AVI BIOPHARMA INC 4575 SW RESEARCH WAY STE 200 CORVALLIS OR 97333-1299 |
(X) | 9A. AMENDMENT OF SOLICIATION NO. | ||||||||||||||||||||||||||
|
¨ |
||||||||||||||||||||||||||||
| 9B. DATED (SEE ITEM 11)
| ||||||||||||||||||||||||||||
| x | 10A. MODIFICATION OF CONTRACT/ORDER NO.
W9113M-10-C-0056 | |||||||||||||||||||||||||||
| 10B. Dated (SEE ITEM 13)
Jul 14, 2010 | ||||||||||||||||||||||||||||
| CODE 49WU1 |
FACILITY CODE |
|||||||||||||||||||||||||||
| 11.THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS | ||||||||||||||||||||||||||||
| ¨ The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers | ¨ is extended, | ¨ is not extended. | ||||||||||||||||||||||||||
|
Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods:
(a) By completing items 8 and 15, and returning copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted;
or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment your desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.
| ||||||||||||||||||||||||||||
| 12. ACCOUNTING AND APPROPIRATION DATA (If required)
See SCHEDULE | ||||||||||||||||||||||||||||
| 13. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14. | ||||||||||||||||||||||||||||
| CHECK ONE |
A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A. | |||||||||||||||||||||||||||
|
¨ |
||||||||||||||||||||||||||||
|
¨ |
B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc. ) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b). | |||||||||||||||||||||||||||
|
x |
C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PRUSUANT TO AUTHORITY OF:
Mutual Agreement of Both Parties | |||||||||||||||||||||||||||
|
x |
D. OTHER (Specify type of modification and authority) | |||||||||||||||||||||||||||
| E. IMPORTANT: |
Contractor ¨ is not, x is required to sign this document and return 1 copies to the issuing office. | |||||||||||||||||||||||||||
| 14. DESCRIPTION OF AMENDMENT/MODIFICATION ( Organized by UCF section headings, including solicitation/contract subject matter where feasible.)
See Attached Summary of Changes.
Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect. | ||||||||||||||||||||||||||||
| 15A. NAME AND TITLE OF SIGNER (Type or print) Chris Garabedian President and CEO |
16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print) Sandra J. O’Connell
Contracting Officer | |||||||||||||||||||||||||||
| 15B. CONTRACTOR/OPERATOR
/s/ Chris Garabedian (Signature of person authorized to sign) |
15C. DATE SIGNED
9/23/11 |
16B. UNITED STATES OF AMERICA
/s/ Sandra J. O’Connell (Signature of Contracting Officer) |
16C. DATE SIGNED
9/26/11 | |||||||||||||||||||||||||
| NSN 7540-01-152-8070 Previous edition unusable |
STANDARD FORM 30 (Rev. 10-83) Prescribed by GSA FAR (48 CFR) 53.243 | |||||||||||||||||||||||||||
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
W9113M-10-C0056
(soconnell 13438)
Page 2 of 3
SECTION SF 30 BLOCK 14 CONTINUATION PAGE
SUMMARY OF CHANGES
| A. | The purpose of this modification is to move studies/tasks originally planned in Option CLINs 0002 and 0006 into CLINs 0001 and 0005 thereby affecting the total cost and schedule of this contract as shown below. |
| 1. | SECTION A—SOLICITATION/CONTRACT FORM |
The total cost of this contract was increased by $46,142,707.00 from $80,396,827.37 to $126,539,534.37.
| 2. | SECTION B—SUPPLIES OR SERVICES AND PRICES |
CLIN 0001
The target cost has increased by $[†] from $[†] to $[†].
The target profit/fee has increased by $[†] from $[†] to $[†].
The minimum profit fee has increased by $[†] from $[†] to $[†].
The maximum profit fee has increased by $[†] from $[†] to $[†].
The total cost of this line item has increased by $[†] from $[†] to $[†].
CLIN 0002
The target cost has decreased by $[†] from $[†] to $[†].
The target profit/fee has decreased by $[†] from $[†] to $[†].
The minimum profit fee has decreased by $[†] from $[†] to $[†].
The maximum profit fee has decreased by $[†] from $[†] to $[†].
The total cost of this line item has decreased by $[†] from $[†] to $[†].
CLIN 0005
The target cost has increased by $[†] from $[†] to $[†].
The target profit/fee has increased by $[†] from $[†] to $[†].
The minimum profit fee has increased by $[†] from $[†] to $[†].
The maximum profit fee has increased by $[†] from $[†] to $[†].
The total cost of this line item has increased by $[†] from $[†] to $[†].
CLIN 0006
The target cost has decreased by $[†] from $[†] to $[†].
The target profit/fee has decreased by $[†] from $[†] to $[†].
The minimum profit fee has decreased by $[†] from $[†] to $[†].
The maximum profit fee has decreased by $[†] from $[†] to $[†].
The total cost of this line item has decreased by $[†] from $[†] to $[†].
| 3. | SECTION F - DELIVERIES OR PERFORMANCE |
The following Delivery Schedule item for CLIN 0001 has been changed from:
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
W9113M-10-C0056
(soconnell 13438)
Page 3 of 3
| DELIVERY DATE |
QUANTITY | SHIP TO ADDRESS | UIC | |||||||
|
25-MAR-2012 |
N/A FOB: Destination |
To:
| DELIVERY DATE | QUANTITY | SHIP TO ADDRESS | UIC | |||
| 18-APR-2013 | N/A FOB: Destination |
The following Delivery Schedule item for CLIN 0005 has been changed from:
| DELIVERY DATE | QUANTITY | SHIP TO ADDRESS | UIC | |||
| 01-APR-2012 | N/A FOB: Destination |
To:
| DELIVERY DATE | QUANTITY | SHIP TO ADDRESS | UIC | |||
| 10-MAY-2013 | N/A FOB: Destination |
4. SECTION J — LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS
Attachment No. 1 Contractor’s Statement of Work — Ebola Virus, Dated 3/11/10 and Attachment No. 2 Contractor’s Statement of Work — Marburg Virus, Dated 3/11/10 are replaced in their entirety with the Attachments to this modification.
| B. | An Integrated Baseline Review (IBR) will be held within 3 months of the date of this modification. At that time the Performance Measurement Baseline (PMB) will be approved by the Government for the changed efforts of CLINs 0001; 0002, 0005 and 0006. A modification will be executed upon acceptance of the PMB, and will incorporate any approved changes to the budget that are required. |
| C. | As a result of this modification all other terms and conditions of this contract are unchanged and remain in full force and effect. |
(End of Summary of Changes)
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Appendix B: Revised Statement of Work
3.0 CONTRACT
AVI BioPharma (AVI) Statement of Work for AVI-6002 as an effective therapeutic for ebolavirus:
3.2 CLIN0001 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.2.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 1 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
3.2.2.1.1 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.2.2.1.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.2.1.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.2.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.2.2.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.2.2.2 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 2 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Period of Work: [†].
Deliverable: [†].
3.2.3 [†]: [†]
[†]
Period of Work: [†].
Deliverable: [†].
3.2.3.1 [†]: [†].
Period of Work: [†].
Deliverable: [†].
3.2.3.1.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.3.1.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.3.1.3 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 3 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
[†]
Period of Work: [†].
Deliverable: [†]
3.2.3.1.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.3.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.3.2.1 [†]: [†]
Period of Work: [†]
Deliverable: [†].
3.2.3.2.2 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 4 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Period of Work: [†].
Deliverable: [†]
3.2.3.2.3 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.2.3.2.4 [†]: [†]
Period of Work: [†]
Deliverable: [†]
3.2.4 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.2.4.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.4.1.1 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 5 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Period of Work: [†].
Deliverable: [†].
3.2.4.1.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.4.1.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.4.1.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.4.1.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.4.2 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 6 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Period of Work: [†].
Deliverable: [†].
3.2.4.2.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.4.2.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.4.2.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.4.2.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.4.2.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 7 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
3.2.4.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.4.3.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.4.3.2 [†]: [†]
Period of Work: [†]
Deliverable: [†]
3.2.4.3.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.4.3.4 [†]: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 8 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Deliverable: [†]
3.2.4.3.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.5 [†]: [†]
Period of Work: [†]
Deliverable: [†]
3.2.5.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.5.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 9 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
3.2.5.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.5.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.5.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.5.6 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.5.7 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.5.8 [†]: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 10 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Deliverable: [†]
3.2.5.9 [†]: [†].
Period of Work: [†].
Deliverable: [†].
3.2.6 [†]: [†]
[†]
Period of Work: [†].
Deliverable: [†].
3.2.6.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.6.2 [†]: [†]
Period of Work: [†].
Deliverable:. [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 11 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
3.2.6.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.7 [†]: [†]
[†]
Period of Work: [†].
Deliverable: [†].
3.2.7.1 [†]: [†].
Period of Work: [†].
Deliverable: [†].
3.2.7.2 Finance and EVMS: [†].
Period of Work: [†].
Deliverable: [†].
3.2.7.3 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.2.7.4 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 12 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Period of Work: [†].
Deliverable: [†].
3.3 [†]: [†]
[†]
Period of Work: [†].
Deliverable: [†].
3.3.1 [†]:[†]
[†]
Period of Work: [†].
Deliverable: [†]
3.3.1.1 [†]: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 13 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Deliverable: [†]
3.3.1.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.2 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.3.2.1 [†]: [†]
Period of Work: [†].
Deliverable: [†]
[†]
3.3.2.1.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 14 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
3.3.2.1.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.2.1.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.2.1.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.2.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.2.2.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 15 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
3.3.2.2.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.2.2.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.2.2.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.2.2.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.2.2.6 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.2.3 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 16 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. |
||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Period of Work: [†].
Deliverable: [†].
3.3.2.3.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.2.3.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.2.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.2.5 [†]: [†]
Period of Work: [†].
Deliverable: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 17 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
3.3.2.6 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.3.1 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.3.3.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.3.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 18 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
3.3.4. [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.4.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.4.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.4.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.4.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.4.5 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 19 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Period of Work: [†].
Deliverable: [†].
3.3.4.6 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.5 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.3.5.1 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 20 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Period of Work: [†].
Deliverable: [†]
3.3.5.2 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.3.5.3 [†]: [†]
Period of Work: [†]
Deliverable: [†]
3.3.6 [†]: [†]
Period of Work: [†].
Deliverable: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 21 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
3.3.6.1 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.3.6.2 [†]: [†]
Periods of Work: [†]
Deliverable: [†]
3.3.6.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.7 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 22 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Period of Work: [†].
Deliverable: [†].
3.3.7.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.7.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
CLIN0001 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.8. [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.8.1 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 23 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Period of Work: [†].
Deliverable: [†].
3.3.8.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.8.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.8.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.8.5 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| ` | Use or disclosure of data contained on this sheet is subject to the | 24 | ||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Period of Work: [†].
Deliverable: [†].
3.3.9 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.9.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.9.2 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.3.9.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.9.4 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 25 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Period of Work: [†].
Deliverable: [†].
3.3.9.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.10 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.10.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.10.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.11 [†]: [†]
Period of Work: [†]
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 26 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
3.3.11.1 [†]: [†]
Period of Work: [†]
Deliverable: [†].
3.3.11.2 [†]: [†]
Period of Work: [†]
Deliverable: [†].
3.3.11.3 [†]: [†]
Period of Work: [†]
Deliverable: [†].
3.3.11.4: [†]. [†]
Period of Work: [†]
Deliverable: [†]
3.3.11.5 [†]. [†]
Period of Work: [†]
Deliverable: [†].
3.3.11.6 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 27 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Period of Work: [†].
Deliverable: [†].
3.3.11.7 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.11.8 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.11.9 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.11.10 [†]: [†]
Period of Work: [†]
Deliverable: [†].
3.3.12 [†]. [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 28 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Period of Work: [†].
Deliverable: [†].
3.3.12.1 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.3.12.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.12.3 [†]: [†]
Period of Work: [†].
Deliverable: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 29 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
3.3.12.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.13 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.3.13.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.13.2 [†]: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 30 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Deliverable: [†].
3.3.13.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.13.4 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.3.13.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.14. [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.14.1 [†]: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 31 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Deliverable: [†].
3.3.14.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.14.3 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.3.15 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.15.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.15.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.15.3 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 32 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Period of Work: [†].
Deliverable: [†].
3.3.16.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.16.1.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.16.1.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.16.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.16.2.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 33 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
3.3.16.2.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.16.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.16.3.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.16.3.2 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.3.17.1 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.3.17.1.1 [†]: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 34 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Deliverable: [†]
3.3.17.1.2 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.3.17.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.17.2.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.17.2.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.17.2.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.17.2.4 [†]: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 35 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Deliverable: [†].
3.3.17.2.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.17.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4 CLIN0002: [†]
Period of Work: [†].
Deliverable: [†].
3.4.1: [†]. [†]
Period of Work: [†].
Deliverable: [†].
3.4.1.1: [†]. [†]
Period of Work: [†].
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 36 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
3.4.1.2 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.4.1.3: [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.2.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 37 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
3.4.2.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.2.3 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.4.2.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.3 [†]: [†]
Period of Work: [†].
Deliverable: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 38 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
3.4.3.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.3.1.1 [†]: [†]
Period of Work: [†]
Deliverable: [†].
3.4.3.1.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.3.1.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.3.1.4 [†]: [†]
Period of Work: [†].
Deliverable: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 39 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
3.4.3.1.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.3.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.3.2.1 [†].[†]
Period of Work: [†].
Deliverable: [†].
3.4.3.2.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.3.2.3 [†]: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 40 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Deliverable: [†].
3.4.3.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.3.4: [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.4.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.4.2 [†]: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 41 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Deliverable: [†].
3.4.4.3 [†]: [†].
Period of Work: [†].
Deliverable: [†].
3.4.4.4 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.4.4.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.4.6 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.4.7 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.5 [†]: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 42 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Deliverable: [†].
3.4.5.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.5.1.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.5.2 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.4.5.3 [†]: [†]
Period of Work: [†]
Deliverable: [†]
3.4.5.4 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 43 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Period of Work: [†].
Deliverable: [†].
3.4.6 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.4.6.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.6.1.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.6.1.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.6.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 44 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
3.4.6.2.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.6.2.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.6.3 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.4.6.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.7 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.7.1 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 45 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Period of Work: [†].
Deliverable: [†].
3.4.7.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.7.3 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.4.7.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.8 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.8.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.8.2 [†]: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 46 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Deliverable: [†].
3.4.8.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.8.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.8.5 [†]: [†].
3.4.8.6 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.8.7 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.8.8 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.4.8.9 [†]: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 47 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Deliverable: [†].
3.4.9 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.9.1 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.4.9.1.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.9.1.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.9.1.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 48 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
3.4.9.2 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.4.9.2.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.9.2.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.9.2.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.9.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.9.4 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 49 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Period of Work: [†].
Deliverable: [†]
3.4.9.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.10 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.10.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.10.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.10.3 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 50 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Period of Work: [†].
Deliverable: [†].
3.4.11 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.4.11.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.11.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.11.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 51 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
3.4.11.4 [†]: [†]
Period of Work: [†]
Deliverable: [†].
3.4.12 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.4.12.1 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.4.12.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.13 [†]: [†]
3.4.14 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.14.1 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 52 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Period of Work: [†].
Deliverable: [†]
3.4.14.1.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.14.1.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.14.1.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.14.1.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.14.2 [†]: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 53 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Deliverable: [†].
3.4.14.2.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.14.2.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.14.2.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.14.2.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.14.2.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.14.3 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 54 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Period of Work: [†].
Deliverable: [†].
3.4.14.3.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.14.3.2 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.4.14.4 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.4.14.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.15 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 55 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Period of Work: [†].
Deliverable: [†].
3.4.15.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.15.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.15.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.15.4 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.5 CLIN0003: [†]
Period of Work: [†].
Deliverable: [†].
3.5.1 [†]: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 56 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
3.5.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.2.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.2.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.2.3 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.5.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.3.1 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.5.3.1.1 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.5.3.1.2 [†]: [†]
Period of Work: [†]
Deliverable: [†].
3.5.3.1.3 [†]: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 57 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Deliverable: [†].
3.5.3.1.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.3.2 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 58 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Period of Work: [†].
Deliverable: [†].
3.5.3.2.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.3.2.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.3.2.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.3.2.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.3.2.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 59 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
3.5.3.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.3.3.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.3.3.2 [†]: [†].
Period of Work: [†].
Deliverable: [†].
3.5.3.4 [†]: [†].
Period of Work: [†].
Deliverable: [†]
3.5.3.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.4 [†]: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 60 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Deliverable: [†].
3.5.4.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.4.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.4.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.4.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.5.1 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.5.5.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.6 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.6.1 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 61 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Period of Work: [†].
Deliverable: [†].
3. 5.6.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.6.3 [†]: [†].
Period of Work: [†].
Deliverable: [†].
3.5.6.4 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.6 CLIN0004: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 62 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Deliverable: [†].
3.6.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.6.1.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.6.1.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.6.1.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.6.2 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 63 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Period of Work: [†].
Deliverable: [†].
3.6.2.1 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.6.2.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.6.3 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.6.3.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 64 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
3.6.3.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.6.3.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.6.3.4 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.6.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.6.4.1 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 65 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Period of Work: [†].
Deliverable: [†].
3.6.4.2 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.6.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.6.5.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.6.5.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.6.6 [†]: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 66 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Deliverable: [†].
3.6.6.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.6.6.2 [†]: [†]
Period of Work: [†]
Deliverable: [†].
3.6.6.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.6.7 [†]: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 67 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Deliverable: [†].
3.6.7.1 Program Management: [†].
Period of Work: [†].
Deliverable: [†].
3.6.7.2 [†]: [†].
Period of Work: [†].
Deliverable: [†].
3.6.7.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.6.7.4 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.6.8 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.6.8.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.6.8.2 [†]: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 68 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-ZEBOV | Final Statement of Work | |||
| 12 August 2011 |
Period of Work: [†].
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 69 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Appendix B: Revised Statement of Work
3.0 CONTRACT
AVI BioPharma (AVI) Statement of Work for AVI-6003 as an effective therapeutic for Marburgvirus:
3.2 CLIN0005 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.2.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 1 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
3.2.2.1.1 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.2.2.1.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.2.1.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.2.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.2.2.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.2.2.2 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 2 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Period of Work: [†].
Deliverable: [†].
3.2.3 [†]: [†]
[†]
Period of Work: [†].
Deliverable: [†].
3.2.3.1 [†]: [†].
Period of Work: [†].
Deliverable: [†].
3.2.3.1.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.3.1.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.3.1.3 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 3 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
[†]
Period of Work: [†].
Deliverable: [†]
3.2.3.1.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.3.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.3.2.1 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 4 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Period of Work: [†]
Deliverable: [†].
3.2.3.2.2 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.2.3.2.3 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.2.3.2.3.1 [†]: [†]
Period of Work: [†]
Deliverable: [†]
3.2.3.2.4 [†]: [†]
Period of Work: [†]
Deliverable: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 5 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
3.2.4 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.2.4.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.4.1.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.4.1.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.4.1.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.4.1.4 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 6 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Period of Work: [†].
Deliverable: [†].
3.2.4.1.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.4.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.4.2.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.4.2.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 7 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
3.2.4.2.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.4.2.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.4.2.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.4.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.4.3.1 [†]: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 8 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Deliverable: [†].
3.2.4.3.2 [†]: [†]
Period of Work: [†]
Deliverable: [†]
3.2.4.3.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.4.3.4 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.2.4.3.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.5 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 9 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Period of Work: [†]
Deliverable: [†]
3.2.5.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.5.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.5.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.5.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.5.5 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 10 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Period of Work: [†].
Deliverable: [†].
3.2.5.6 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.5.7 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.2.5.8 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.2.5.9 [†]: [†].
Period of Work: [†].
Deliverable: [†].
3.2.6 [†]: [†]
3.2.6.3 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 11 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Period of Work: [†].
3.2.7 [†]: [†]
[†]
Period of Work: [†].
Deliverable: [†].
3.2.7.1 [†]: [†].
Period of Work: [†].
Deliverable: [†].
3.2.7.2 Finance and EVMS: [†].
Period of Work: [†].
Deliverable: [†].
3.2.7.3 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.2.7.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 12 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
3.3 [†]: [†]
[†]
Period of Work: [†].
Deliverable: [†].
3.3.1 [†]: [†]
[†]
Period of Work: [†].
Deliverable: [†]
3.3.1.1 [†]: [†]
Period of Work: [†].
Deliverable: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 13 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
3.3.1.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.2.1 [†]: [†]
Period of Work: [†].
Deliverable: [†]
[†]
3.3.2.1.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.2.1.2 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 14 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Period of Work: [†].
Deliverable: [†].
3.3.2.1.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.2.1.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.2.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.2.2.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.2.2.2 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 15 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Period of Work: [†].
Deliverable: [†].
3.3.2.2.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.2.2.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.2.2.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.2.2.6 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.2.3 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 16 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Period of Work: [†].
Deliverable: [†].
3.3.2.3.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.2.3.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.2.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.2.5 [†]: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 17 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Deliverable: [†]
3.3.2.6 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.3.1 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.3.3.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 18 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
3.3.4. [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.4.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.4.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.4.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.4.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 19 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
3.3.4.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.4.6 [†]:
[†]
Period of Work: [†].
Deliverable: [†].
3.3.5 [†]: [†]
Period of Work: [†].
Deliverable: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 20 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
3.3.5.1 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.3.5.2 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.3.5.3 [†]: [†]
Period of Work: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 21 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Deliverable: [†]
3.3.6 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.3.6.1 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.3.6.2 [†]: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 22 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Deliverable: [†]
3.3.6.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.7 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.7.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.7.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
CLIN0005 [†]: [†]
Period of Work: [†].
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 23 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
3.3.8. [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.8.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.8.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.8.3 [†]: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 24 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Deliverable: [†].
3.3.8.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.8.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.9 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.9.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 25 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
3.3.9.2 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.3.9.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.9.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.9.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.10 [†]: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 26 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Deliverable: [†].
3.3.10.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.10.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.11 [†]: [†]
Period of Work: [†]
Deliverable: [†].
3.3.11.1 [†]: [†]
Period of Work: [†]
Deliverable: [†].
3.3.11.2 [†]: [†]
Period of Work: [†]
Deliverable: [†].
3.3.11.3 [†]: [†]
Period of Work: [†]
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 27 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
3.3.11.4: [†]. [†]
Period of Work: [†]
Deliverable: [†]
3.3.11.5 [†]. [†]
Period of Work: [†]
Deliverable: [†].
3.3.11.6 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.11.7 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.11.8 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 28 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Period of Work: [†].
Deliverable: [†].
3.3.11.9 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.11.10 [†]: [†]
Period of Work: [†]
Deliverable: [†].
3.3.12 [†]. [†]
Period of Work: [†].
Deliverable: [†].
3.3.12.1 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 29 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Period of Work: [†].
Deliverable: [†]
3.3.12.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.12.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.12.4 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 30 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Period of Work: [†].
Deliverable: [†].
3.3.13 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.3.13.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.13.2 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.3.13.3 [†]: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 31 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Deliverable: [†].
3.3.13.4 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.3.13.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.14. [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.14.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.14.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 32 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
3.3.14.3 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.3.15 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.15.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.15.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.15.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.16.1 [†]: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 33 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Deliverable: [†].
3.3.16.1.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.16.1.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.16.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.16.2.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.16.2.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 34 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
3.3.16.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.16.3.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.16.3.2 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.3.17.1 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.3.17.1.1 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.3.17.1.2 [†]: [†]
Period of Work: [†].
Deliverable: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 35 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
3.3.17.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.17.2.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.17.2.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.17.2.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.17.2.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.3.17.2.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 36 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
3.3.17.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4 CLIN0006: [†]
Period of Work: [†].
Deliverable: [†].
3.4.1: [†]. [†]
Period of Work: [†].
Deliverable: [†].
3.4.1.1: [†]. [†]
Period of Work: [†].
Deliverable: [†].
3.4.1.2 [†]: [†]
Period of Work: [†].
Deliverable: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 37 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
3.4.1.3: [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.2.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.2.2 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 38 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Period of Work: [†].
Deliverable: [†].
3.4.2.3 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.4.2.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.3 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.4.3.1 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 39 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Period of Work: [†].
Deliverable: [†].
3.4.3.1.1 [†]: [†]
Period of Work: [†]
Deliverable: [†].
3.4.3.1.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.3.1.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.3.1.4 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.4.3.1.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 40 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
3.4.3.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.3.2.1 [†]. [†]
Period of Work: [†].
Deliverable: [†].
3.4.3.2.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.3.2.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.3.3 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 41 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Period of Work: [†].
Deliverable: [†].
3.4.3.4: [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.4.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.4.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 42 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
3.4.4.3 [†]: [†].
Period of Work: [†].
Deliverable: [†].
3.4.4.4 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.4.4.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.4.6 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.4.7 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.5 [†]: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 43 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Deliverable: [†].
3.4.5.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.5.1.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.5.2 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.4.5.3 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.4.5.4 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 44 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Period of Work: [†].
Deliverable: [†].
3.4.6 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.4.6.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.6.1.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.6.1.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.6.2 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 45 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Period of Work: [†].
Deliverable: [†].
3.4.6.2.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.6.2.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.6.3 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.4.6.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.7 [†]: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 46 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Deliverable: [†].
3.4.7.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.7.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.7.3 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.4.7.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.8 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.8.1 [†]: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 47 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Deliverable: [†].
3.4.8.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.8.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.8.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.8.5 [†]: [†].
3.4.8.6 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.8.7 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.8.8 [†]: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 48 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Deliverable: [†]
3.4.8.9 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.9 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.9.1 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.4.9.1.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.9.1.2 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 49 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Period of Work: [†].
Deliverable: [†].
3.4.9.1.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.9.2 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.4.9.2.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.9.2.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.9.2.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.9.3 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 50 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Period of Work: [†].
Deliverable: [†].
3.4.9.4 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.4.9.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.10 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.10.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 51 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
3.4.10.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.10.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.11 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.4.11.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 52 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
3.4.11.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.11.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.11.4 [†]: [†]
Period of Work: [†]
Deliverable: [†].
3.4.12 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.4.12.1 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.4.12.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 53 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
3.4.13 [†]: [†]
3.4.14 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.14.1 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.4.14.1.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.14.1.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.14.1.3 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 54 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Period of Work: [†].
Deliverable: [†].
3.4.14.1.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.14.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.14.2.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.14.2.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 55 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
3.4.14.2.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.14.2.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.14.2.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.14.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.14.3.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.14.3.2 [†]: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 56 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Deliverable: [†]
3.4.14.4 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.4.14.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.15 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.15.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 57 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
3.4.15.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.15.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.4.15.4 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.5 CLIN0007: [†]
Period of Work: [†].
Deliverable: [†].
3.5.1 [†]: [†].
3.5.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.2.1 [†]: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 58 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Deliverable: [†].
3.5.2.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.2.3 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.5.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.3.1 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.5.3.1.1 [†]: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 59 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Deliverable: [†]
3.5.3.1.2 [†]: [†]
Period of Work: [†]
Deliverable: [†].
3.5.3.1.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.3.1.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.3.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.3.2.1 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 60 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Period of Work: [†].
Deliverable: [†].
3.5.3.2.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.3.2.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.3.2.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.3.2.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.3.3 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 61 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Period of Work: [†].
Deliverable: [†].
3.5.3.3.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.3.3.2 [†]: [†].
Period of Work: [†].
Deliverable: [†].
3.5.3.4 [†]: [†].
Period of Work: [†].
Deliverable: [†]
3.5.3.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.4.1 [†]: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 62 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Deliverable: [†].
3.5.4.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.4.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.4.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.5.1 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.5.5.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.6 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 63 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Period of Work: [†].
Deliverable: [†].
3.5.6.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3. 5.6.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.5.6.3 [†]: [†].
Period of Work: [†].
Deliverable: [†].
3.5.6.4 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.6 CLIN0008: [†]
Period of Work: [†].
Deliverable: [†].
3.6.1 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 64 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Period of Work: [†].
Deliverable: [†].
3.6.1.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.6.1.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.6.1.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.6.2 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 65 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Period of Work: [†].
Deliverable: [†].
3.6.2.1 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.6.2.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.6.3 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.6.3.1 [†]: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 66 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Deliverable: [†].
3.6.3.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.6.3.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.6.3.4 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.6.4 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.6.4.1 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 67 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Period of Work: [†].
Deliverable: [†].
3.6.4.2 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.6.5 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.6.5.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.6.5.2 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.6.6 [†]: [†]
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 68 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Period of Work: [†].
Deliverable: [†].
3.6.6.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.6.6.2 [†]: [†]
Period of Work: [†]
Deliverable: [†].
3.6.6.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 69 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
3.6.7 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.6.7.1 Program Management: [†].
Period of Work: [†].
Deliverable: [†].
3.6.7.2 [†]: [†].
Period of Work: [†].
Deliverable: [†].
3.6.7.3 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.6.7.4 [†]: [†]
Period of Work: [†].
Deliverable: [†]
3.6.8 [†]: [†]
Period of Work: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 70 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |
| AVI BioPharma, Inc. | ||||
| HFV-MARV | Final Change Proposal: Statement of Work | |||
| 16 September 2011 |
Deliverable: [†].
3.6.8.1 [†]: [†]
Period of Work: [†].
Deliverable: [†].
3.6.8.2 [†]: [†].
Period of Work: [†].
Deliverable: [†].
| † | DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION. |
| Use or disclosure of data contained on this sheet is subject to the | 71 | |||
| W9113M-09-R-0008 | restriction on the title page of this proposal. |